Gene therapy lets a French teen dodge sickle cell disease – Kansas City Star


Kansas City Star
Gene therapy lets a French teen dodge sickle cell disease
Kansas City Star
A French teen who was given gene therapy for sickle cell disease more than two years ago now has enough properly working red blood cells to dodge the effects of the disorder, researchers report. The first-in-the-world case is detailed in Thursday's New ...
Gene Therapy Treats Sickle Cell Disease in Teenager Using Lentiviral VectorMedscape
Gene therapy 'cures' boy of blood disease that affects millions | New ...New Scientist
Gene Therapy: A Breakthrough for Sickle Cell Anemia?Philly.com

all 9 news articles »

Original post:
Gene therapy lets a French teen dodge sickle cell disease - Kansas City Star

Embryo Experiments Reveal Earliest Human Development, But Stir Ethical Debate – NPR

Notes This is a seven-day-old embryo that scientists kept alive in a laboratory dish. If it developed further, the clusters in green would become cells that shape the body and the red/purple cells would form the placenta.

Ali Brivanlou slides open a glass door at the Rockefeller University in New York to show off his latest experiments probing the mysteries of the human embryo.

"As you can see, all my lab is glass just to make sure there is nothing that happens in some dark rooms that gives people some weird ideas," says Brivanlou, perhaps only half joking.

Brivanlou knows that some of his research makes some people uncomfortable. That's one reason he's agreed to give me a look at what's going on.

His lab and one other discovered how to keep human embryos alive in lab dishes longer than ever before at least 14 days. That's triggered an international debate about a long-standing convention (one that's legally binding in some countries, though not in the U.S.) that prohibits studying human embryos that have developed beyond the two-week stage.

Ali Brivanlou's research team at Rockefeller University in New York was one of two groups internationally that figured out how to keep human embryos alive in lab dishes beyond the 14-day stage of development. Rob Stein/NPR hide caption

And in other experiments, he's using human stem cells to create entities that resemble certain aspects of primitive embryos. Though Brivanlou doesn't think these "embryoids" would be capable of developing into fully formed embryos, their creation has stirred debate about whether embryoids should be subject to the 14-day rule.

Brivanlou says he welcomes these debates. But he hopes society can reach a consensus to permit his work to continue, so he can answer some of humanity's most fundamental questions.

"If I can provide a glimpse of, 'Where did we come from? What happened to us, for us to get here?' I think that, to me, is a strong enough rationale to continue pushing this," he says.

For decades, scientists thought the longest an embryo could survive outside the womb was only about a week. But Brivanlou's lab, and one in Britain, announced last year in the journals Nature and Nature Cell Biology that they had kept human embryos alive for two weeks for the first time.

That enabled the scientists to study living human embryos at a crucial point in their development, a time when they're usually hidden in a woman's womb.

"Women don't even know they are pregnant at that stage. So it has always been a big black box," Brivanlou says.

Gist Croft, a stem cell biologist in Brivanlou's lab, shows me some samples, starting with one that's 12 days old.

"So you can see this with the naked eye," Croft says, pointing to a dish. "In the middle of this well, if you look down, there's a little white speck it looks like a grain of sand or a piece of dust."

Under a microscope, the embryo looks like a fragile ball of overlapping bubbles shimmering in a silvery light with thin hair-like structures extending from all sides.

Croft and Brivanlou explain that those willowy structures are what embryos would normally extend at this stage to search for a place to implant inside the uterus. Scientists used to think embryos could only do that if they were receiving instructions from the mother's body.

"The amazing thing is that it's doing its thing without any information from mom," Brivanlou says. "It just has all the information already in it. That was mind-blowing to me."

The embryos they managed to keep alive in in the lab dish beyond seven days of development have also started secreting hormones and organizing themselves to form the cells needed to create all the tissues and organs in the human body.

The two scientists think studying embryos at this and later stages could lead to discoveries that might point to new ways to stop miscarriages, treat infertility and prevent birth defects.

"The only way to understand what goes wrong is to understand what happens normally, or as normally as we can, so we can prevent all of this," Brivanlou says.

The 14-day cutoff

But Brivanlou isn't keeping these embryos alive longer than 14 days because of the rule.

A long-standing rule prohibits scientists from keeping human embryos alive more than two weeks, after which the central nervous system starts to develop. The 14-day rule, was developed decades ago to avoid raising too many ethical questions about experimenting on human embryos. It's a law in some countries, and just a guideline in the U.S.

"The decision about pulling the plug was probably the toughest decision I've made in my scientific career," he says. "It was sad for me."

The 14-day rule was developed decades ago to avoid raising too many ethical questions about experimenting on human embryos.

Two weeks is usually the moment when the central nervous system starts to appear in the embryo in a structure known as the "primitive streak."

It's also roughly the stage at which an embryo can no longer split into twins. The idea behind the rule is, that's when an embryo becomes a unique individual.

But the rule was initiated when no one thought it would ever be possible to keep embryos growing in a lab beyond two weeks. Brivanlou thinks it's time to re-think the 14-day rule.

"This is the moment," he says.

Scientists, bioethicists and others are debating the issue in the U.S., Britain and other countries. The rule is law in Britain and other countries and incorporated into widely followed guidelines in the United States.

Insoo Hyun, a bioethicist at Case Western Reserve University, advocates revisiting the rule. It would allow more research to be done on embryos that are destined to be destroyed anyway, he says embryos donated by couples who have finished infertility treatment.

"Given that it has to be destroyed," Hyun says, "some would argue that it's best to get as much information as possible scientifically from it before you destroy it."

But others find it morally repugnant to use human embryos for research at any stage of their development and argue that lifting the 14-day rule would make matters worse.

"Pushing it beyond 14 days only aggravates what is the primary problem, which is using human life in its earliest stages solely for experimental purposes," says Dr. Daniel Sulmasy, a Georgetown University bioethicist.

The idea of extending the 14-day rule even makes some people who support embryo research queasy, especially without first finding another clear stopping point.

Hank Greely, a Stanford University bioethicist, worries that going beyond 14 days could "really draws into question whether we're using humans or things that are well along the path to humans purely as guinea pigs and purely as experimental animals."

Embryo alternative: 'Embryoids'

So as that debate continues, Brivanlou and his colleagues are trying to develop another approach. The scientists are attempting to coax human embryonic stem cells to organize themselves into entities that resemble human embryos. They are also using induced pluripotent stem (iPS) cells, which are cells that behave like embryonic stem cells, but can be made from any cell in the body.

Embryoids like this one are created from stem cells and resemble very primitive human embryos. Scientist hope to use them to learn more about basic human biology and development. Courtesy of Rockefeller University hide caption

Embryoids like this one are created from stem cells and resemble very primitive human embryos. Scientist hope to use them to learn more about basic human biology and development.

Brivanlou's lab has already shown that these "embryo-like structures" or "embryoids" can create the three fundamental cell types in the human body.

But the scientists have only been able to go so far using flat lab dishes. So the researchers are now trying to grow these embryonic-like structures in three dimensions by placing stem cells in a gel.

"Essentially, we're trying to, in a way, to recreate a human embryo in a dish starting from stem cells," says Mijo Simunovic, another of Brivanlou's colleagues.

In early experiments, Simonovic says, he's been able to get stem cells to "spontaneously" form a ball with a "cavity in its center." That's significant because that's what early human embryos do in the uterus.

Simunovic says it's unclear how close these structures could become to human embryos entities that have the capability to develop into babies.

"At the moment, we don't know. That's something that's very hot for us right now to try to understand," Simunovic says.

Simunovic argues the scientists are not "ethically limited to studying these cells and studying these structures" by the 14-day rule.

There's a debate about that, however.

"At what point is your model of an embryo basically an embryo?" asks Hyun, especially when the model seems to have "almost like this inner, budding life."

"Are we creating life that, in the right circumstances, if you were to transfer this to the womb it would continue its journey?" he asks.

Dr. George Daley, the dean of the Harvard Medical School and a leading stem cell researcher, says scientists have been preparing for the day when stem-cell research might raise such questions.

"I think what prospects people are concerned about are the kinds of dystopian worlds that were written about by Aldous Huxley in Brave New World," Daley says. "Where human reproduction is done on a highly mechanized scale in a petri dish."

Daley stresses scientists are nowhere near that, and may never get there. But science moves quickly. So Daley says it's important scientists move carefully with close ethical scrutiny.

The latest guidelines issued by the International Society for Stem Cell Research call for intensive ethical review, Daley notes.

Brivanlou acknowledges that some of his experiments have produced early signs of the primitive streak. But that's a very long way from being able to develop a spinal cord, or flesh and bones, let alone a brain. He dismisses the notion that the research on embryoids would ever lead to scientists creating humans in a lab dish.

"They will not get up start walking around. I can assure you that," he says, noting that full human embryonic development is a highly complex process that requires just the right mix of the biology, physics, geometry and other factors.

Nevertheless, Brivanlou says all of his experiments go through many layers of review. And he's convinced the research should continue.

"It would be a travesty," he says, "to decide that, somehow, ignorance is bliss."

Continue reading here:
Embryo Experiments Reveal Earliest Human Development, But Stir Ethical Debate - NPR

ISSCR 2017 – Drug Target Review

event

Date: 14 June 2017 - 17 June 2017

Location: Boston Convention and Exhibition Center 415 Summer Street Boston 02210 United States

Website: ISSCR2017.org

Email: [emailprotected]

Telephone: +1 224-592-5700

The International Society for Stem Cell Research (ISSCR) 2017 annual meeting will be held 14-17 June in Boston, Mass., U.S., at the Boston Convention and Exhibition Center. The meeting brings together 4000 stem cell researchers and clinicians from around the world to share the latest developments in stem cell research and regenerative medicine. In a series of lectures, workshops, poster presentations, and a dynamic exhibition floor, researchers focus on recent findings, technological advances, trends, and innovations that are realizing progress in using stem cells in the discovery and validation of novel treatments.

In 2017, the ISSCR is expanding its translational and clinical programming with two half-day, pre-meeting educational sessions geared toward bringing new therapies to the clinic. The Workshop on Clinical Translation (WCT) and the Clinical Advances in Stem Cell Research (CASC) programs are designed for scientists and physicians interested in learning more about the process of developing stem cell-based therapies and advances in stem cell applications in the clinic.

The Presidential Symposium recognizes a decade of progress in iPS cell research and application with a distinguished lineup of speakers including Shinya Yamanaka, discoverer of iPSCs. Additional plenary presentations include distinguished speakers from around the world focusing on organoids and organogenesis, the making of tissues and organs; stem cells and cancer; chromatin and RNA biology; stress, senescence and aging; tissue regeneration and homeostasis; and the frontiers of cell therapy.

Concurrent sessions feature new and innovative developments across the breadth of the field, and incorporate more than 100 abstract-selected speakers. Disease modelling, tissue engineering, stem cell niches, epigenetics, hematopoietic stem cells, and gene modification and gene editing are just a few of the 28 topic areas presented.

Other meeting offerings include career development sessions and networking opportunities. A full listing of the ISSCR 2017 meeting programming can be found at ISSCR2017.org.

Map

42.3461949 -71.04563680000001

Original post:
ISSCR 2017 - Drug Target Review

StemBioSys Lands Experimental UT Tech That Finds Young Stem Cells – Xconomy

Xconomy Texas

San Antonio StemBioSys, the life sciences company with a system for growing stem cells, has licensed an experimental technology from University of Texas Health San Antonio that may help identify healthy young adult stem cells among large pools of other cells.

Theres plenty of research examining how to possibly use adult stem cells as treatments for medical conditions, ranging from cardiac disease to metabolic disorders, but current uses are rather limited to therapies like bone-marrow transplants for blood disorders, especially in children. Treatments that use patients own stem cells may be safer than using stem cells from someone else because they might reduce the potential for an immune response, according to StemBioSys CEO Bob Hutchens. Thats still theoretical, he says.

Finding large quantities of usable adult stem cells is difficult, though. StemBioSys believes its new technology can potentially identify a few thousand high-quality, young stem cells from a sample of tens of thousands of cells taken from a patient, Hutchens sayspotentially being a key word.

The research is quite earlythe technology has only been studied in animal models and in vitro, and StemBioSys is in the process of applying for federal grants to take the research into animal trials. If StemBioSys new intellectual property can successfully isolate the stem cells, Hutchens says they could grow more of them with StemBioSys core product.

StemBioSys sells a so-called extracellular matrix product made of proteins that provide a hospitable environment for stem cells, helping them divide and produce more stem cells.

Whats intriguing to us is that its a really interesting application of our technology, Hutchens says. You take this combination of identifying this very small population of young healthy cells in elderly people, and use our technology to expand it.

If the company can indeed find the young stem cells of a single patient and replicate them, it would give researchers and physician an accessible pool of the cells that theyd want for potential stem cell transplants and other treatments, Hutchens says.

Terms of the deal werent disclosed. StemBioSys, which was founded based on other University of Texas System research, acquired a portfolio of issued and pending patents. Famed MIT researcher and Xconomist Robert Langer is on the companys board of directors.

Again, theres plenty to prove out with this early stage research, so it will take time before any potential commercialization comes to fruition. Travis Block, the researcher who helpeddevelopthe technology while earning his PhD. last year at the University of Texas Health Science Center at San Antonio, will help shepherd the project along and other regenerative medicine work as StemBioSyss senior scientist.

David Holley is Xconomy's national correspondent based in Austin, TX. You can reach him at dholley@xconomy.com

Read more:
StemBioSys Lands Experimental UT Tech That Finds Young Stem Cells - Xconomy

How to Find the Right Stem Cell Clinic – Good4Utah

Dr. Khan from Wasatch Pain Solutions explained which stem cell clinic you should choose for treatment. Dr Khan is the only Regenexxprovider in Utah and he performs the most scientifically advanced stem cell procedures for spine and orthopedic conditions. While it seems many different clinics offer stem cell procedures, they are different because most are using amniotic fluid from another person, instead of your own bone marrow stem cells.

Amniotic stem cells go through extensive processing (which includes gamma radiation) in order to become safe for injection into a new person. During this process, almost all of the stem cells that were alive have been killed off. So essentially you arent getting any stem cells from these injections, but you are still paying the price. Wasatch Pain Solutions uses bone marrow derived stem cells because research has shown it is the most effective and safe way for treating your injuries.

Regenexx is hands down the best option for orthopedic stem cell procedures in the world. Dont be fooled by pop up clinics using amniotic fluid promoted as stem cell therapy. Contact Dr. Khan at Wasatchpainsolutions.com or give them a call 801-302-2690 to see what the most advanced stem cell and blood platelet treatment options could mean for you.

This story includes sponsored content.

Here is the original post:
How to Find the Right Stem Cell Clinic - Good4Utah

Cell death in gut implicated in bowel disease – Medical Xpress

March 1, 2017 by George Lowery Phagocytes within small, finger-like projections in the small intestine called villi. Credit: Cornell University

The natural life cycle of cells that line the intestine is critical to preserving stable conditions in the gut, according to new research led by a Weill Cornell Medicine investigator. The findings may lead to the development of new therapies to alleviate inflammatory bowel disease (IBD) and other chronic inflammatory illnesses.

In the study, published Nov. 9 in Nature, the scientists investigated the healthy turnover of epithelial cells, which are born and die every four to five days, to better understand how the gut maintains a healthy equilibrium. Because cells, called phagocytes, can clear dying cells so quickly in the body, it had been difficult to study this process in tissues. The inability to clear dying cells has been linked to inflammation and autoimmunity. Dying epithelial cells are shed into the gut lumen, so their active clearance is not necessary and they were thought to have no role in intestinal inflammation.

The investigators sought to understand whether phagocytes can take up dying epithelial cells in the gut and, if so, how these phagocytes respond. Specifically, the study tried to ascertain which genes are expressed by phagocytes after the uptake of dead cells. To answer these questions, the scientists engineered a mouse model where they could turn on apoptosis and catch phagocytes in the act of sampling dying cells. Through a series of experiments, they found that several of the genes modulated up or down in phagocytes bearing dead cells overlapped with the same genes that have been associated with susceptibility to IBD.

"The fact that there was an overlap shows that apoptosis must play a role in maintaining equilibrium in the gut," said Julie Magarian Blander, a senior faculty member in the Jill Roberts Institute for Research in Inflammatory Bowel Disease at Weill Cornell Medicine who was recently recruited as a professor of immunology from Mount Sinai. "This study identified cell death within the epithelium as an important factor to consider when thinking about therapeutic strategies for patients with IBD."

In their experiments, the scientists expressed a green fluorescent protein fused to the diphtheria toxin receptor within intestinal epithelial cells of mice, which made them visible under a microscope and sensitive to diphtheria toxin. They injected into the intestinal walls of these mice a carefully titrated dose of toxin to induce cell death. Then the team examined the phagocytes that turned green after they internalized dead cells. Macrophages, one kind of phagocyte, expressed genes that help process the increased lipid and cholesterol load they acquired from dying cells. Dendritic cells, another type of phagocyte, activated genes responsible for instructing the development of regulatory CD4 T cells, a class of suppressive white blood cells. Notably, both phagocytes expressed a common "suppression of inflammation" gene signature.

Because the same genes that confer susceptibility to IBD were modulated in response to apoptotic cell sampling, the research indicates that a disruption of the phagocytes' immunosuppressive response would have consequences for homeostasis or stable conditions in the gut.

"We know there is excessive cell death, inflammation and microbial imbalance in IBD, so the prediction is that the immunosuppressive program in phagocytes, associated with natural cell death in the gut epithelium, would be disrupted," Blander said. "The goal in the treatment of IBD is to enhance healing in the gut, but now we know that this also helps phagocytes restore their immunosuppressive and homeostatic functions. We think this would translate into helping patients stay in remission. There's a lot to learn from phagocytes, and we may be able to target the same pathways they use to suppress inflammation in patients with IBD."

The study validates the importance of healing in the mucosa, or lining, of the intestine as a therapy and enhances the understanding of that process. The next phase of Blander's research will be to investigate how the inflammatory conditions of IBD alter cell death and the homeostatic immunosuppressive functions of intestinal phagocytes, in both mouse models and different groups of IBD patients undergoing anti-TNF therapy at the Jill Roberts Center for Inflammatory Bowel Disease at New York-Presbyterian and Weill Cornell Medicine.

Explore further: Pac-Man like protein which eats dead cells could help in the fight against cancer

More information: Ryan J. Cummings et al. Different tissue phagocytes sample apoptotic cells to direct distinct homeostasis programs, Nature (2016). DOI: 10.1038/nature20138

Journal reference: Nature

Provided by: Cornell University

Scientists at the University of Sheffield have identified a protein which causes cells to eat their dying neighbours, helping to prevent inflammation - something which is vital in the fight to stop cancer spreading.

A discovery about how the body deals with the cholesterol contained within its dying cells has suggested an exciting new approach to control people's cholesterol levels and thus their risk of developing heart disease.

Institute scientists have revealed a potent inflammatory molecule released by dying cells triggers inflammation during necroptosis, a recently described form of cell death linked to inflammatory disease.

An enzyme that plays an active role in inflammation could be a natural way to suppress tumors and ulcers in the colon that are found in colitis associated cancer (CAC), a type of colorectal cancer that is driven by chronic ...

(HealthDay)The cytokine M-CSF promotes survival of lung and liver mononuclear phagocytes to mediate host defense during bacterial pneumonia, according to an experimental study published in the June 15 issue of The Journal ...

The renin-angiotensin system (RAS) plays an important role in regulating the body's fluid levels and blood pressure. However, a new signal path in the RAS may also have a substantial influence on immune cells, as a recent ...

The natural life cycle of cells that line the intestine is critical to preserving stable conditions in the gut, according to new research led by a Weill Cornell Medicine investigator. The findings may lead to the development ...

Researchers at Cardiff University have discovered that genetic variation is the reason why some immune systems overreact to viruses.

Scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified a new regulator of the innate immune responsethe immediate, natural immune response to foreign invaders. The study, published recently ...

A new discovery by researchers at the Fred Hutchinson Cancer Research Center in Seattle makes an important step in identifying which specific T cells within the diverse army of a person's immune system are best suited to ...

As much as we try to avoid it, we are constantly sharing germs with those around us. But even when two people have the same infection, the resulting illnesses can be dramatically differentmild for one person, severe or ...

Scientists propose in Nature blocking a molecule that drives inflammation and organ damage in Gaucher and maybe other lysosomal storage diseases as a possible treatment with fewer risks and lower costs than current therapies.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

View post:
Cell death in gut implicated in bowel disease - Medical Xpress

Teen Thinks She’s Alone During Her Medical Treatment. Then She Notices the Cell Phone at Her Feet – Independent Journal Review

She thought she was alone in the room during her dermatology treatment.But that was before she saw the cell phone.

AsThe Morning Call reports,the 17-year-old girl had been receiving light treatments for a skin condition at Penn Medicine Dermatology in Lower Makefield, Pennsylvania. James Close, a 45-year-old licensed practical nurse, was the technician assigned to help the teen during hertreatments.

On this occasion, the girlundressed and entered the light booth as usual. But as the treatment started, she noticed an iPhone on the floor. Worse, she could see her nude reflection on the screen.

That's when she realized the phone was recording live video and it had been recording her in the nude for about 25 seconds.

Distressed, the teen brought the phone to the clinic's staff, who contacted the police. According to WPVI News, police searched the phone (which was identified as belonging to Close) and found 18videos ofpatients in the light booth.

Bucks County District Attorney's Office

The New York Post reports that the videos depicted the teen and sevenother female patients all of whom were unaware they were being filmed.

Four of the women were totally nude in the video clips and one was undressed from the waist down. Close's voice can be heard in a few of the videos and in one, his face can be seen.

According to the date stamps, Close made the videos between January 18 and February 13. They ranged from 13seconds to three minutes long. There are also threemore videos of the teen girl.

Penn Medicine would not disclose how long Close was an employee or whether he had any previous discipline issues. In a statement to the Post, a Penn Medicine spokeswoman said:

We are appalled at the actions of this former employee and are cooperating fully with the police as they investigate this very disturbing matter.

Now Close has been arrested and charged with more than 45 crimes, including filming a nude child and 36 counts of invasion of privacy. He is currently being held at Bucks County Correctional Facility on $100,000 bail.

Follow this link:
Teen Thinks She's Alone During Her Medical Treatment. Then She Notices the Cell Phone at Her Feet - Independent Journal Review

Kite’s CAR T-Cell Therapy Success – The Scientist


The Scientist
Kite's CAR T-Cell Therapy Success
The Scientist
Last year, both Juno Therapeutics and Kite Pharma announced that a small number of patients had died in their respective CAR T-cell therapy trials. Juno's trial was halted, but Kite's carried on. The Kite study enrolled 77 patients with advanced ...
Gene therapy "seems extraordinary" at fighting blood cancer in study, experts sayCBS News
Terminal cancer patients in complete remission after one gene therapy treatmentTelegraph.co.uk
With Eye On FDA, Kite Says CAR-T For Lymphoma Holds Up After 6 MonthsXconomy
Inquirer.net -Everyday Health (blog) -talkRADIO (press release) -Kite Pharma, Inc. | Investor Relations
all 109 news articles »

Excerpt from:
Kite's CAR T-Cell Therapy Success - The Scientist

Angels Pitcher Put Off Surgery for Stem Cell Treatment – Athletic Business (blog)

Garrett Richards' first thought when he found out about his torn elbow ligament in May was to schedule Tommy John surgery as soon as possible.

It made sense, considering the ligament-replacement procedure has become the standard fix for such injuries. Plus, the Los Angeles Angels ace was familiar with the operating room, having had surgery for a ruptured patellar tendon he suffered on Aug. 20, 2014, toward the end of a breakout season.

Richards knew how to handle the seemingly interminable months of rehab, and he wanted to get the clock started on his return.

But a conversation with Angels head physical therapist Bernard Li convinced Richards to consider other alternatives, and in mid-May he tried a relatively novel treatment in which stem cells taken from bone marrow in his pelvis were injected into the damaged area.

Richards did not pitch again the rest of the year except for a stint in the instructional league, but he has been back on the mound throwing bullpen sessions since the first day of Angels camp and reported no problems.

This weekend, Richards anticipates pitching in a game for the first time since May 1, when his aching elbow forced him from a start after four innings.

"It's nice to know I'll be able to start the season this year and kind of pick up where I left off," Richards said.

A couple of lockers away, fellow starter Andrew Heaney had a different tale to tell.

The promising left-hander also went down with a torn ulnar collateral ligament early in the season, after making one start. Their ailments were the two biggest blows to an Angels rotation that was decimated by injuries, dooming the club to a 74-88 record and a fourth-place finish in the AL West.

Heaney also tried stem cell therapy, two weeks before Richards, both under the supervision of team doctor Steve Yoon. Heaney's ligament didn't heal, though, and after experiencing discomfort throwing after his rehab, he had Tommy John surgery July 1. He has been ruled out for the 2017 season.

"They tell you it's 50-50. It either works, or it doesn't," Heaney said of the stem cell procedure. "Obviously, me and Garrett are pretty much the proof of that rule."

Even with less-favorable odds than reconstructive surgery, which has an 80% success rate for returning to action and 67% for pitching 10 games or more, stem cell therapy is gaining acceptance as an option for pitchers with partial UCL tears. The recovery time is shorter -- three to five months instead of 12 to 18 -- and the treatment less invasive.

There are limitations. Biological approaches based on stem cells or platelet-rich plasma (PRP) won't repair a complete tear of the ligament. The location of the injury and its extent factor into the chances of success. And players whose ligaments don't recover, then have to have surgery, extending their window of time for returning to action.

Even then, the idea of healing without going under the knife is becoming increasingly appealing. New York Yankees ace Masahiro Tanaka treated the small tear in his elbow ligament with PRP and rehabilitation in 2014, sitting out 10 weeks but coming back to pitch in late September.

He's 26-11 with a 3.26 ERA over the last two seasons, raising the profile of PRP -- a procedure in which the player's own blood is used to promote healing of the injury -- as a non-surgical alternative.

Now Richards looms as the test case for stem cell treatment to fix partial UCL tears, which make up about 60-70% of these injuries. If the hard-throwing right-hander can return to his old form -- he was a Cy Young Award candidate before his knee injury in August2014 -- other pitchers in his situation are bound to at least consider the route he took.

"I hope this opens another path for guys," Richards said. "Obviously, if you can prevent being cut on and having surgery, that's the No.1 priority. I hope guys don't just jump right into Tommy John, that they at least explore this option."

Ageless veteran Bartolo Colon was the first pitcher widely known to have undergone stem cell therapy as he sought to recover from elbow and shoulder ailments in 2010. At the time, the ethics of the procedure were questioned, especially because the doctor who performed it, South Florida-based Joseph Purita, acknowledged using human growth hormone in previous treatments, though not in Colon's.

Since then, the use of stem cells has become more mainstream. They are the focus of Yoon's practice.

"As more and more people start to use it, you're getting a better sense for what it can and can't do," Yoon said. "Baseball definitely has opened up to it quite a bit, and as we see some of the successes like with Garrett, we're getting a better understanding that there's a lot of potential here with these types of treatment."

Yoon calls stem cell therapy a "super PRP" because it combines the curative properties of that treatment with more healing agents and says it can be used on tendon tears, muscle tears and strains and even to address degenerative joint disease.

However, much remains unknown about the benefits of stem cells. Lyle Cain, an orthopedist who has performed Tommy John surgeries and stem cell treatments at the Andrews Sports Medicine & Orthopaedic Center in Birmingham, Ala., said most of the research has been anecdotal, not scientific.

"We still don't have a good understanding even four or five years into it exactly what the stem cells do, what their method is," Cain said. "The theory is there's probably a chemical reaction where it releases chemicals in the cell that help the healing process.

"The stem cells aren't necessarily put in there with the thought they're going to become ligament, but there's probably a cellular chemical mechanism that helps the healing response."

And as Heaney discovered, they're not always effective. His tear was located farther down the arm, which reduced his chances of success with stem cell therapy. Richards was a better candidate because his injury, though deemed "high grade," was located within the ligament, like a slit on a rubber band.

But because Heaney was looking at likely missing most or all of 2017 even if he had surgery right away, he decided to try stem cells. The timing of the injury plays a major role in whether pitchers contemplate alternatives to surgery, with the more conservative approach often recommended if it happens early in the season.

Heaney said he doesn't regret taking that route and would have been upset if he had undergone the ligament-replacement operation right away, only to find out he could have returned to action quicker through another means.

"I'm glad it worked for him," he said of Richards. "It would have been really awful if it hadn't worked for either of us. Then we'd both look like idiots."

Their peers are paying attention. In a major league pitching community where about a quarter of its members have had Tommy John surgery, interest in the effectiveness of alternative cures is high.

The Los Angeles Dodgers' Brandon McCarthy was not a candidate because his ligament tore clear off the bone but said he had heard positive reports about stem cell treatment, not so much about PRP.

The Pittsburgh Pirates' Daniel Hudson, a veteran of two Tommy Johns, is encouraged as well.

"It's supposed to help repair the tissue. Before, ligaments just won't repair themselves," Hudson said. "It might keep a lot of guys from going under the knife."

That's Cain's hope. He regularly treats UCL tears on high school, college and minor league players with stem cells or PRP, but realizes there's heightened pressure on major leaguers to return to the field.

If more of them can do it without visiting an operating room, it would represent a major advancement for the players and the industry.

"There will be certain ligaments that are damaged enough that we don't have an answer; they have to reconstruct," Cain says. "But I think overall, if you look 15 years down the road, I suspect we'll be doing a lot more non-surgical treatment than surgical treatment."

Contributing: Gabe Lacques in Bradenton, Fla.

Read More of Today's AB Headlines

Subscribe to Our Daily E-Newsletter

Follow this link:
Angels Pitcher Put Off Surgery for Stem Cell Treatment - Athletic Business (blog)

Stem cell therapy can help treat diabetic heart disease – The … – Economic Times

KARAIKAL: Recent advancements in stem cells research have given hope for successfully treating diabetic heart disease (DHD), renowned New Zealand-based researcher in cardiovascular diseases Dr Rajesh Katare said today.

DHD affected the muscular tissues of the heart leading to complications and it had been demonstrated that resident stem cells of myocardium can be stimulated to repair and replace e degenerated cardiac myocytes resulting in a novel therapeutic effect and ultimately cardiac regeneration, he said.

Katare, Director of Cardiovascular Research Division in the University of Otago, New Zealand, was delivering the keynote address at the continuing medical education programme on "Role of Micro-RNAs and stem cells in cardiac regeneration in diabetic heart disease" at the Karaikal campus of premier health institute JIPMER.

Presenting clinical evidences, Katare said stem cell therapy certainly presented a new hope for successfully treating DHD.

Jawaharlal Institute of Post Graduate Medical Education (JIPMER) Director Dr Subash Chandra Parija pointed out that it was the first such programme on the role of stem cells in cardiac regeneration in the whole of the country.

He said as diabetes was highly prevalent in the country, providing treatment for DHD had become a big challenge. Patients suffering from the condition have to undergo lifelong treatment and medications. "In this backdrop, advancements in stem cell therapy assume significance," he said.

Excerpt from:
Stem cell therapy can help treat diabetic heart disease - The ... - Economic Times